{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:50:52Z","timestamp":1782208252565,"version":"3.54.5"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12325-026-03597-1","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T05:54:56Z","timestamp":1778478896000},"page":"3187-3203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Journey of Adult Patients with Lyme Disease in the United States: A Qualitative Interview Study and Patient-Reported, Health-Related Quality-of-Life Assessment"],"prefix":"10.1007","volume":"43","author":[{"given":"L. Hannah","family":"Gould","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda R.","family":"Mercadante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Fairhurst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Burns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Duench","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8625-4201","authenticated-orcid":false,"given":"Holly","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"issue":"2","key":"3597_CR1","doi-asserted-by":"publisher","first-page":"616","DOI":"10.3201\/eid2702.202731","volume":"27","author":"KJ Kugeler","year":"2021","unstructured":"Kugeler KJ, Schwartz AM, Delorey MJ, Mead PS, Hinckley AF. Estimating the frequency of Lyme disease diagnoses, United States, 2010-2018. Emerg Infect Dis. 2021;27(2):616\u20139. https:\/\/doi.org\/10.3201\/eid2702.202731.","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"3597_CR2","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1542\/pir.35-12-500","volume":"35","author":"ED Shapiro","year":"2014","unstructured":"Shapiro ED. Borrelia burgdorferi (Lyme disease). Pediatr Rv. 2014;35(12):500\u20139. https:\/\/doi.org\/10.1542\/pir.35-12-500.","journal-title":"Pediatr Rv"},{"issue":"3","key":"3597_CR3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.idc.2022.03.004","volume":"36","author":"P Mead","year":"2022","unstructured":"Mead P. Epidemiology of Lyme disease. Infect Dis Clin North Am. 2022;36(3):495\u2013521. https:\/\/doi.org\/10.1016\/j.idc.2022.03.004.","journal-title":"Infect Dis Clin North Am"},{"key":"3597_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2016.90","volume":"2","author":"AC Steere","year":"2016","unstructured":"Steere AC, Strle F, Wormser GP, et al. Lyme borreliosis. Nat Rev Dis Primers. 2016;2:16090. https:\/\/doi.org\/10.1038\/nrdp.2016.90.","journal-title":"Nat Rev Dis Primers"},{"key":"3597_CR5","unstructured":"National Notifiable Diseases Surveillance System (NNDSS). Lyme Disease (Borrelia burgdorferi) 2017 Case Definition. 2021. https:\/\/ndc.services.cdc.gov\/case-definitions\/lyme-disease-2017\/#print. Accessed 13 Feb 2026."},{"issue":"1","key":"3597_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/cid\/ciaa1215","volume":"72","author":"PM Lantos","year":"2021","unstructured":"Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical practice guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021;72(1):1\u20138. https:\/\/doi.org\/10.1093\/cid\/ciaa1215.","journal-title":"Clin Infect Dis"},{"key":"3597_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ijid.2022.01.033","volume":"116","author":"JN Aucott","year":"2022","unstructured":"Aucott JN, Yang T, Yoon I, Powell D, Geller SA, Rebman AW. Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: a prospective cohort study. Int J Infect Dis. 2022;116:230\u20137. https:\/\/doi.org\/10.1016\/j.ijid.2022.01.033.","journal-title":"Int J Infect Dis"},{"key":"3597_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2021.100142","volume":"6","author":"J Ursinus","year":"2021","unstructured":"Ursinus J, Vrijmoeth HD, Harms MG, et al. Prevalence of persistent symptoms after treatment for Lyme borreliosis: a prospective observational cohort study. Lancet Reg Health Eur. 2021;6:100142. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100142.","journal-title":"Lancet Reg Health Eur"},{"issue":"11","key":"3597_CR9","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1007\/s00415-015-7891-4","volume":"262","author":"R Dersch","year":"2015","unstructured":"Dersch R, Sarnes AA, Maul M, et al. Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis. J Neurol. 2015;262(11):2572\u20137. https:\/\/doi.org\/10.1007\/s00415-015-7891-4.","journal-title":"J Neurol"},{"issue":"5","key":"3597_CR10","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1600-0404.2010.01482.x","volume":"124","author":"R Eikeland","year":"2011","unstructured":"Eikeland R, Mygland A, Herlofson K, Lj\u00f8stad U. European neuroborreliosis: quality of life 30\u00a0months after treatment. Acta Neurol Scand. 2011;124(5):349\u201354. https:\/\/doi.org\/10.1111\/j.1600-0404.2010.01482.x.","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"3597_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.1595","volume":"10","author":"R Eikeland","year":"2020","unstructured":"Eikeland R, Lj\u00f8stad U, Helgeland G, et al. Patient-reported outcome after treatment for definite Lyme neuroborreliosis. Brain Behav. 2020;10(4):e01595. https:\/\/doi.org\/10.1002\/brb3.1595.","journal-title":"Brain Behav"},{"key":"3597_CR12","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12883-015-0386-1","volume":"15","author":"H Schmidt","year":"2015","unstructured":"Schmidt H, Djukic M, Jung K, et al. Neurocognitive functions and brain atrophy after proven neuroborreliosis: a case-control study. BMC Neurol. 2015;15:139. https:\/\/doi.org\/10.1186\/s12883-015-0386-1.","journal-title":"BMC Neurol"},{"issue":"1","key":"3597_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5114\/reum.2022.114352","volume":"60","author":"VV Yuskevych","year":"2022","unstructured":"Yuskevych VV, Zhulkevych IV, Makhovska OS, Smiyan SI. Assessment of quality of life in patients with Lyme arthritis and rheumatoid arthritis. Reumatologia. 2022;60(1):35\u201341. https:\/\/doi.org\/10.5114\/reum.2022.114352.","journal-title":"Reumatologia"},{"issue":"8","key":"3597_CR14","first-page":"30","volume":"104","author":"SE Vargas","year":"2021","unstructured":"Vargas SE, Guillen M, Stout CD, et al. Characterizing post-treatment Lyme disease syndrome: a mixed methods study of patients at a Lyme disease clinic in Rhode Island. R I Med J. 2021;104(8):30\u20134.","journal-title":"R I Med J"},{"issue":"6","key":"3597_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.psym.2013.04.003","volume":"54","author":"AM Chandra","year":"2013","unstructured":"Chandra AM, Keilp JG, Fallon BA. Correlates of perceived health-related quality of life in post-treatment Lyme encephalopathy. Psychosomatics. 2013;54(6):552\u20139. https:\/\/doi.org\/10.1016\/j.psym.2013.04.003.","journal-title":"Psychosomatics"},{"issue":"5","key":"3597_CR16","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337\u201343. https:\/\/doi.org\/10.3109\/07853890109002087.","journal-title":"Ann Med"},{"key":"3597_CR17","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: methods to identify what is important to patients: guidance for industry, food and drug administration staff, and other stakeholders. 2022. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-methods-identify-what-important-patients. Accessed 13 Jan 2026."},{"key":"3597_CR18","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: collecting comprehensive and representative input. 2020. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-collecting-comprehensive-and-representative-input. Accessed 13 Jan 2026."},{"issue":"9","key":"3597_CR19","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1097\/ACM.0000000000000388","volume":"89","author":"BC O\u2019Brien","year":"2014","unstructured":"O\u2019Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245\u201351. https:\/\/doi.org\/10.1097\/ACM.0000000000000388.","journal-title":"Acad Med"},{"issue":"9","key":"3597_CR20","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.7326\/M22-1460","volume":"175","author":"LM DeTora","year":"2022","unstructured":"DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 2022;175(9):1298\u2013304. https:\/\/doi.org\/10.7326\/M22-1460.","journal-title":"Ann Intern Med"},{"issue":"2","key":"3597_CR21","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40258-017-0310-5","volume":"15","author":"NJ Devlin","year":"2017","unstructured":"Devlin NJ, Brooks R. EQ-5D and the EuroQol Group: past, present and future. Appl Health Econ Health Policy. 2017;15(2):127\u201337. https:\/\/doi.org\/10.1007\/s40258-017-0310-5.","journal-title":"Appl Health Econ Health Policy"},{"key":"3597_CR22","unstructured":"ATLAS.ti. The interview analysis tool that helps you leverage every piece of data. 2025. https:\/\/atlasti.com\/interview-analysis-tools. Accessed 16 Dec 2025."},{"issue":"9","key":"3597_CR23","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE. Three approaches to qualitative content analysis. Qual Health Res. 2005;15(9):1277\u201388. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"},{"issue":"9","key":"3597_CR24","first-page":"1408","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20(9):1408\u201316.","journal-title":"Qual Rep"},{"issue":"1","key":"3597_CR25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/jan.15479","volume":"79","author":"EL Davies","year":"2023","unstructured":"Davies EL, Bulto LN, Walsh A, et al. Reporting and conducting patient journey mapping research in healthcare: a scoping review. J Adv Nurs. 2023;79(1):83\u2013100. https:\/\/doi.org\/10.1111\/jan.15479.","journal-title":"J Adv Nurs"},{"issue":"3","key":"3597_CR26","doi-asserted-by":"publisher","first-page":"196","DOI":"10.4997\/JRCPE.2015.304","volume":"45","author":"S Mavin","year":"2015","unstructured":"Mavin S, Watson EJ, Evans R. Distribution and presentation of Lyme borreliosis in Scotland - analysis of data from a national testing laboratory. J R Coll Physicians Edinb. 2015;45(3):196\u2013200. https:\/\/doi.org\/10.4997\/JRCPE.2015.304.","journal-title":"J R Coll Physicians Edinb"},{"issue":"Suppl 6","key":"3597_CR27","doi-asserted-by":"publisher","first-page":"S1435","DOI":"10.1093\/clinids\/11.Supplement_6.S1435","volume":"11","author":"CA Ciesielski","year":"1989","unstructured":"Ciesielski CA, Markowitz LE, Horsley R, Hightower AW, Russell H, Broome CV. Lyme disease surveillance in the United States, 1983-1986. Rev Infect Dis. 1989;11(Suppl 6):S1435\u201341.","journal-title":"Rev Infect Dis"},{"issue":"4","key":"3597_CR28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/zph.13107","volume":"71","author":"JH Stark","year":"2024","unstructured":"Stark JH, McFadden B, Patel N, Kelly PH, Gould LH, Riis J. Intention to vaccinate for Lyme disease using the Health Belief Model. Zoonoses Public Health. 2024;71(4):349\u201358. https:\/\/doi.org\/10.1111\/zph.13107.","journal-title":"Zoonoses Public Health"},{"issue":"6","key":"3597_CR29","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1093\/jme\/tjac137","volume":"59","author":"SI Brummitt","year":"2022","unstructured":"Brummitt SI, Harvey DJ, Smith WA, Barker CM, Kjemtrup AM. Assessment of physician knowledge, attitudes, and practice for Lyme disease in a low-incidence state. J Med Entomol. 2022;59(6):2182\u20138. https:\/\/doi.org\/10.1093\/jme\/tjac137.","journal-title":"J Med Entomol"},{"issue":"6","key":"3597_CR30","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.ttbdis.2015.06.005","volume":"6","author":"JD Forrester","year":"2015","unstructured":"Forrester JD, Brett M, Matthias J, et al. Epidemiology of Lyme disease in low-incidence states. Ticks Tick-Borne Dis. 2015;6(6):721\u20133. https:\/\/doi.org\/10.1016\/j.ttbdis.2015.06.005.","journal-title":"Ticks Tick-Borne Dis"},{"issue":"7","key":"3597_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofz299","volume":"6","author":"T Kobayashi","year":"2019","unstructured":"Kobayashi T, Higgins Y, Samuels R, et al. Misdiagnosis of Lyme disease with unnecessary antimicrobial treatment characterizes patients referred to an academic infectious diseases clinic. Open Forum Infect Dis. 2019;6(7):ofz299. https:\/\/doi.org\/10.1093\/ofid\/ofz299.","journal-title":"Open Forum Infect Dis"},{"issue":"6","key":"3597_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-021367","volume":"8","author":"AG Hirsch","year":"2018","unstructured":"Hirsch AG, Herman RJ, Rebman A, et al. Obstacles to diagnosis and treatment of Lyme disease in the USA: a qualitative study. BMJ Open. 2018;8(6):e021367. https:\/\/doi.org\/10.1136\/bmjopen-2017-021367.","journal-title":"BMJ Open"},{"key":"3597_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00283","volume":"6","author":"BA Fallon","year":"2019","unstructured":"Fallon BA, Zubcevik N, Bennett C, et al. The General Symptom Questionnaire-30 (GSQ-30): a brief measure of multi-system symptom burden in Lyme disease. Front Med. 2019;6:283. https:\/\/doi.org\/10.3389\/fmed.2019.00283.","journal-title":"Front Med"},{"issue":"3","key":"3597_CR34","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s11136-020-02650-y","volume":"30","author":"R Jiang","year":"2021","unstructured":"Jiang R, Janssen MFB, Pickard AS. US population norms for the EQ-5D-5L and comparison of norms from face-to-face and online samples. Qual Life Res. 2021;30(3):803\u201316. https:\/\/doi.org\/10.1007\/s11136-020-02650-y.","journal-title":"Qual Life Res"},{"issue":"12","key":"3597_CR35","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1093\/cid\/ciw189","volume":"62","author":"AB Wills","year":"2016","unstructured":"Wills AB, Spaulding AB, Adjemian J, et al. Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. Clin Infect Dis. 2016;62(12):1546\u201351. https:\/\/doi.org\/10.1093\/cid\/ciw189.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"3597_CR36","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1111\/j.0737-1209.2006.230104.x","volume":"23","author":"D Drew","year":"2006","unstructured":"Drew D, Hewitt H. A qualitative approach to understanding patients\u2019 diagnosis of Lyme disease. Public Health Nurs. 2006;23(1):20\u20136. https:\/\/doi.org\/10.1111\/j.0737-1209.2006.230104.x.","journal-title":"Public Health Nurs"},{"issue":"7","key":"3597_CR37","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, et al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839\u201342. https:\/\/doi.org\/10.1016\/j.jval.2017.11.014.","journal-title":"Value Health"},{"issue":"1","key":"3597_CR38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L. How many interviews are enough? An experiment with data saturation and variability. Field Methods. 2006;18(1):59\u201382.","journal-title":"Field Methods"},{"issue":"22","key":"3597_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6622a1","volume":"66","author":"AM Schwartz","year":"2017","unstructured":"Schwartz AM, Hinckley AF, Mead PS, Hook SA, Kugeler KJ. Surveillance for Lyme disease - United States, 2008-2015. MMWR Surveill Summ. 2017;66(22):1\u201312. https:\/\/doi.org\/10.15585\/mmwr.ss6622a1.","journal-title":"MMWR Surveill Summ"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03597-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03597-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03597-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T09:22:30Z","timestamp":1782206550000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03597-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["3597"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03597-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L. Hannah Gould, Alexander Davidson, Stephanie A. Duench, and Holly Yu are employees of Pfizer Inc. and may hold stock or stock options. Amanda R. Mercadante was a Pfizer employee at the time of this study and is now unaffiliated. Chris Marshall, Stephanie Fairhurst, Greg Davis, and Danielle Burns are employees and stockholders of Clarivate Analytics. Clarivate Analytics provides consultancy to various pharmaceutical and biotechnology companies, including Pfizer who was the sponsor of this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All study materials received IRB approval from Western Copernicus Group, an independent review board (approval number 1360766, initial approval date 25 September 2023). Before the interview, participants signed an informed consent form indicating their agreement to participate and for study results to be published. An honorarium was provided after the interview to compensate participants for the time spent participating in the study. This study complied with relevant laws and institutional guidelines and was conducted in accordance with the Declaration of Helsinki. Participant\u2019s privacy rights were observed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}